{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T12:41:52Z","timestamp":1768999312142,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003787","name":"Natural Science Foundation of Hebei Province","doi-asserted-by":"publisher","award":["H2022329002"],"award-info":[{"award-number":["H2022329002"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.jpba.2023.115652","type":"journal-article","created":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T03:16:18Z","timestamp":1692414978000},"page":"115652","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Determination of five mTOR inhibitors in human plasma for hepatocellular carcinoma treatment using QuEChERS-UHPLC-MS\/MS"],"prefix":"10.1016","volume":"235","author":[{"given":"Ting","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengcheng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanmei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2023.115652_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.216048","article-title":"Human liver cancer organoids: Biological applications, current challenges, and prospects in hepatoma therapy","volume":"555","author":"Chen","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jpba.2023.115652_bib2","article-title":"Cabozantinib for HCC treatment, from clinical back to experimental models","volume":"11","author":"Deng","year":"2021"},{"key":"10.1016\/j.jpba.2023.115652_bib3","article-title":"Targeted therapy for hepatocellular carcinoma","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.jpba.2023.115652_bib4","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-019-0754-1","article-title":"Targeting mTOR for cancer therapy","volume":"12","author":"Hua","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jpba.2023.115652_bib5","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/cam4.150","article-title":"Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma \u2013 systematic review and meta\u2010analysis","volume":"2","author":"Yamanaka","year":"2013","journal-title":"Cancer Med."},{"key":"10.1016\/j.jpba.2023.115652_bib6","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/lt.22292","article-title":"Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis","volume":"17","author":"Saliba","year":"2011","journal-title":"Liver Transplant."},{"key":"10.1016\/j.jpba.2023.115652_bib7","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3892\/or.2013.2890","article-title":"AZD8055 induces cell death associated with autophagy and activation of AMPK in hepatocellular carcinoma","volume":"31","author":"Hu","year":"2014","journal-title":"Oncol. Rep."},{"issue":"7","key":"10.1016\/j.jpba.2023.115652_bib8","first-page":"1056","article-title":"[Antitumor effects of AZD2014, a dual mTORC1\/2 inhibitor, against human hepatocellular carcinoma xenograft in nude mice]","volume":"41","author":"Liao","year":"2021","journal-title":"Nan Fang. Yi Ke Da Xue Xue Bao"},{"key":"10.1016\/j.jpba.2023.115652_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114436","article-title":"Validation of a rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of vistusertib","volume":"208","author":"Scott","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2023.115652_bib10","article-title":"Pictilisib enhances the antitumor effect of doxorubicin and prevents tumor-mediated bone destruction by blockade of PI3K\/AKT pathway","volume":"10","author":"Liang","year":"2021"},{"key":"10.1016\/j.jpba.2023.115652_bib11","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdt202.22","article-title":"A phase I\/II study of mTOR inhibitor temsirolimus in patients with unresectable hepatocellular carcinoma (HCC)","volume":"24","author":"Yeo","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jpba.2023.115652_bib12","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.transproceed.2019.01.069","article-title":"Trough levels of everolimus are associated with recurrence rates of hepatocellular carcinoma after liver transplantation","volume":"51","author":"Cholongitas","year":"2019","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.jpba.2023.115652_bib13","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/CCO.0b013e32835de8ee","article-title":"Temsirolimus in the treatment of mantle cell lymphoma","volume":"25","author":"Bouabdallah","year":"2013","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.jpba.2023.115652_bib14","doi-asserted-by":"crossref","unstructured":"Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-co %J Annals of Oncology. 27 (2016) 2059\u20132066.\u3008https:\/\/doi.org\/10.1093\/annonc\/mdw320\u3009.","DOI":"10.1093\/annonc\/mdw320"},{"key":"10.1016\/j.jpba.2023.115652_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2022.1047","article-title":"Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor\u2212Positive Recurrent or Metastatic Endometrial Cancer","volume":"8","author":"Heudel","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.jpba.2023.115652_bib16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","article-title":"Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer","volume":"85","author":"Yu","year":"2022","journal-title":"Semin Cancer Biol."},{"key":"10.1016\/j.jpba.2023.115652_bib17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cca.2019.07.026","article-title":"A high-throughput LC-MS\/MS method for the quantification of four immunosu- ppressants drugs in whole blood","volume":"498","author":"Gong","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jpba.2023.115652_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26020425","article-title":"Development and validation of a bioanalytical LC-MS\/MS method for simultaneous determination of sirolimus in porcine whole blood and lung tissue and pharmacokinetic application with coronary stents","volume":"26","author":"Nguyen","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.jpba.2023.115652_bib19","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/rcm.323","article-title":"High-throughput semi-automated 96-well liquid\/liquid extraction and liquid chromatography\/mass spectrometric analysis of everolimus (RAD 001) and cyclosporin a (CsA) in whole blood","volume":"15","author":"Brignol","year":"2001","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.jpba.2023.115652_bib20","first-page":"695","article-title":"Salting out-assisted liquid\u2013liquid extraction for liquid chromatography\u2013tandem mass spectrometry measurement of tacrolimus, sirolimus, everolimus, and cyclosporine a in whole blood","volume":"42","author":"Kvams\u00f8e","year":"2020"},{"key":"10.1016\/j.jpba.2023.115652_bib21","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/01.ftd.0000148451.35811.74","article-title":"Effective use of liquid chromatography-mass spectrometry (LC\/MS) in the routine clinical laboratory for monitoring sirolimus, tacrolimus, and cyclosporine","volume":"27","author":"Poquette","year":"2005","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jpba.2023.115652_bib22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.clinbiochem.2019.11.006","article-title":"An isotope dilution LC-MS\/MS based candidate reference method for the quantification of cyclosporine A, tacrolimus, sirolimus and everolimus in human whole blood","volume":"82","author":"Taibon","year":"2020","journal-title":"Clin. Biochem"},{"key":"10.1016\/j.jpba.2023.115652_bib23","article-title":"Rapid determination of 9 tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma in human plasma by QuEChERS-UPLC-MS\/MS","volume":"13","author":"Jiang","year":"2022","journal-title":"Front Pharm."},{"key":"10.1016\/j.jpba.2023.115652_bib24","unstructured":"Food and Drug Administration(FDA), 2018. Bioanalytical Method Validation Guidance for Industry. 2018. Bioanalytical Method Validation Guidance for Industry (fda.gov)."},{"key":"10.1016\/j.jpba.2023.115652_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115316","article-title":"LC-MS\/MS method for simultaneous quantification of osilodrostat and metyrapone in human plasma from patients treated for Cushing's Syndrome","volume":"228","author":"Balakirouchenane","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2023.115652_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115382","article-title":"Determination of olverembatinib in human plasma and cerebrospinal fluid by an LC-MS\/MS method: Validation and clinical application","volume":"230","author":"Xiang","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2023.115652_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115601","article-title":"Development and validation of an LC-MS\/MS method for simultaneous determination of EVT201 and its five metabolites in human plasma: application to a clinical study in Chinese healthy subjects","volume":"235","author":"Zhang","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2023.115652_bib28","first-page":"632","article-title":"Development and validation of the new liquid chromatography-tandem mass spectrometry method for the determination of unbound tacrolimus in the plasma ultrafiltrate of transplant recipients","volume":"14","author":"Bodnar-Broniarczyk","year":"2022"},{"key":"10.1016\/j.jpba.2023.115652_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2020.105647","article-title":"Determination of nine mental drugs in human plasma using solid-phase supported liquid-liquid extraction and HPLC-MS\/MS","volume":"160","author":"Zheng","year":"2021","journal-title":"Microchem. J."},{"key":"10.1016\/j.jpba.2023.115652_bib30","article-title":"QuEChERS-Based approach to the extraction of five calcium channel blockers from plasma determined by UPLC-MS\/MS","volume":"28","author":"Zhao","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.jpba.2023.115652_bib31","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1007\/s00216-017-0317-7","article-title":"Simultaneous determination of multiclass pesticide residues in human plasma using a mini QuEChERS method","volume":"409","author":"Srivastava","year":"2017","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2023.115652_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2020.110660","article-title":"Optimization of QuEChERS extraction for detection and quantification of 20 antidepressants in postmortem blood samples by LC-MS\/MS","volume":"319","author":"Camp\u00ealo","year":"2021","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.jpba.2023.115652_bib33","article-title":"Optimization of a Multiresidue Analysis of 65 Pesticides in Surface Water Using Solid-Phase Extraction by","volume":"26","author":"Nakhjavan","year":"2021","journal-title":"LC-MS\/MS"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523004211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523004211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:34:19Z","timestamp":1760002459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708523004211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":33,"alternative-id":["S0731708523004211"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115652","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determination of five mTOR inhibitors in human plasma for hepatocellular carcinoma treatment using QuEChERS-UHPLC-MS\/MS","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115652","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115652"}}